Literature DB >> 4024029

A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

G Bratt, E Törnebohm, D Lockner, K Bergström.   

Abstract

The pharmacokinetics of a heparin fragment of low molecular weight (LMWH) of 4000-5000 D and unfractioned standard heparin (UFH) have been studied after i.v. injections of different doses and infusions in 8 humans. The heparin activity was significantly higher and the effect on APTT lower after LMWH fragment as compared to UFH in the same doses. The half-life of heparin activity was about 1 hr for UFH and about 2 hr for LMWH. LMWH was found to be eliminated according to first order kinetics and there were no signs of dose dependency.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4024029

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  [Different effectiveness of two preparations of low molecular weight heparin in patients with elective hip joint replacement].

Authors:  U Weber; K Koppenhagen; H Mälzer; M Matthes
Journal:  Langenbecks Arch Chir       Date:  1991

2.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

3.  A low molecular weight heparin in hemodialysis.

Authors:  N Maurin; H Kierdorf
Journal:  Klin Wochenschr       Date:  1988-03-15

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

5.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

7.  A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.

Authors:  R A Steiner; K Keller; T Lüscher; W E Schreiner
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 8.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

9.  Evidence of an absorption phase after short intravenous suramin infusions.

Authors:  P R Hutson; K Tutsch; D Spriggs; M Christian; R Rago; R Mutch; G Wilding
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice.

Authors:  S Frizelle; J Schwarz; S A Huber; K Leslie
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.